NCT04327037View on ClinicalTrials.gov

Safety of Expanded Haploidentical Natural Killer Cells for Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 2, 2019

Primary Completion Date

June 6, 2021

Study Completion Date

June 30, 2021

Conditions
Leukemia, Acute MyeloidLeukemia, Acute Lymphoblastic
Interventions
BIOLOGICAL

Expanded Haploidentical Natural Killer cells

One dose (from 20x to \>100x 10\^6 /kg) of expanded haploidentical NK cells

DRUG

IL-2

6 doses of IL-2 (1 × 10\^6 units/m2) from -1 day every other day.

Trial Locations (1)

223053

Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk

All Listed Sponsors
lead

Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

OTHER

NCT04327037 - Safety of Expanded Haploidentical Natural Killer Cells for Leukemia | Biotech Hunter | Biotech Hunter